OncoResponse Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Series 2

  • Latest Deal Amount
  • $6M

  • Investors
  • 25

OncoResponse General Information

Description

Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of patients who have responded exceptionally well to checkpoint inhibition. The company leverages a proprietary B-cell technology platform to develop cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system, helping doctors and patients to combat cancer optimally.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 609 Main Street
  • Suite 4200
  • Houston, TX 77002
  • United States
+1 (206)
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Vertical(s)
Corporate Office
  • 609 Main Street
  • Suite 4200
  • Houston, TX 77002
  • United States
+1 (206)

OncoResponse Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoResponse Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series 2) 06-May-2025 $6M Completed Clinical Trials - Phase 2
7. Grant 13-Jun-2023 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series D) 01-May-2023 Completed Clinical Trials - Phase 2
5. General Corporate Purpose 15-Feb-2022 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series C) 25-Mar-2021 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 14-Jun-2019 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 23-Mar-2017 $29.5M $29.5M Completed Pre-Clinical Trials
1. Joint Venture 18-Aug-2015 Completed Startup
To view OncoResponse’s complete valuation and funding history, request access »

OncoResponse Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series 1
To view OncoResponse’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

OncoResponse Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of patien
Drug Discovery
Houston, TX
11 As of 2025

Framingham, MA
 

Philadelphia, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoResponse Competitors (107)

One of OncoResponse’s 107 competitors is RootPath, a Venture Capital-Backed company based in Framingham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
RootPath Venture Capital-Backed Framingham, MA
Aro Biotherapeutics Venture Capital-Backed Philadelphia, PA
Marengo Therapeutics Venture Capital-Backed Cambridge, MA
AnTolRx Formerly VC-backed Cambridge, MA
Geneos Therapeutics Venture Capital-Backed Philadelphia, PA
You’re viewing 5 of 107 competitors. Get the full list »

OncoResponse Patents

OncoResponse Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4695304-A2 Lilrb2/1 antibody products and methods Pending 13-Apr-2023
US-20250002577-A1 Lilrb2/1 antibody products and methods Pending 13-Apr-2023
WO-2024216139-A2 Lilrb2/1 antibody products and methods Inactive 13-Apr-2023
WO-2024216139-A3 Lilrb2/1 antibody products and methods Inactive 13-Apr-2023
AU-2023365813-A1 Lilrb2 antibody products and methods Pending 18-Oct-2022 C07K16/2803
To view OncoResponse’s complete patent history, request access »

OncoResponse Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoResponse Investors (25)

Investor Name Investor Type Holding Investor Since Participating Rounds
Oxford Finance Lender/Debt Provider Minority
Cancer Prevention and Research Institute of Texas Government
Bering Capital Venture Capital Minority
InterVest Venture Capital Minority
Magnetar Capital Hedge Fund Minority
You’re viewing 5 of 25 investors. Get the full list »

OncoResponse Acquisitions (1)

OncoResponse’s most recent deal was a Merger/Acquisition with Paganini Biopharma. The deal was made on 07-Nov-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Paganini Biopharma 07-Nov-2017 Merger/Acquisition Buildings and Property
To view OncoResponse’s complete acquisitions history, request access »

OncoResponse FAQs

  • When was OncoResponse founded?

    OncoResponse was founded in 2015.

  • Where is OncoResponse headquartered?

    OncoResponse is headquartered in Houston, TX.

  • What is the size of OncoResponse?

    OncoResponse has 11 total employees.

  • What industry is OncoResponse in?

    OncoResponse’s primary industry is Drug Discovery.

  • Is OncoResponse a private or public company?

    OncoResponse is a Private company.

  • What is OncoResponse’s current revenue?

    The current revenue for OncoResponse is .

  • How much funding has OncoResponse raised over time?

    OncoResponse has raised $180M.

  • Who are OncoResponse’s investors?

    Oxford Finance, Cancer Prevention and Research Institute of Texas, Bering Capital, InterVest, and Magnetar Capital are 5 of 25 investors who have invested in OncoResponse.

  • Who are OncoResponse’s competitors?

    RootPath, Aro Biotherapeutics, Marengo Therapeutics, AnTolRx, and Geneos Therapeutics are some of the 107 competitors of OncoResponse.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process